The op-ed exchange between President Trump and Senator Sanders over “Medicare for all” this week is worth some of your attention. But since that debate won’t be escaping us anytime soon, here are some other health stories from the week to pay attention to:
- There’s a new deputy administrator and director of Medicaid at CMS. Many are questioning the appointment of the former commissioner of the Maine DHHS, who is an ardent opponent of Medicaid expansion, and what this might mean for the program.
- 2019 certainly doesn’t promise to be a year of bipartisan compromise. But the one issue that may motivate legislators to reach across the aisle after November is still drug pricing.
- In an effort to improve transparency and address drug pricing, the Trump Administration has proposed that drugmakers reveal list prices of their medications in TV ads. How might such a rule be enforced and what implications does it have for actually lowering prices?
- In response to increased pressure on the pharmaceutical industry’s drug pricing, pharma PACs continue to pour money into congressional committees with jurisdiction over pharmaceutical issues. These graphics highlight just how much.
- In a state with a volatile political landscape, where Republicans are battling to maintain representation and Democrats have their hopes high, seniors with healthcare on their minds are likely to decide the most contested races in Pennsylvania.
- Though Medicare for All may shed the U.S. of some high administrative costs, it may also shed private-plan features that many people appreciate or rely on.
- Like other Republicans up for reelection, Rep. Cathy McMorris Rodgers, who voted for the House Repeal Bill of the ACA, is facing major Democratic backlash to the GOPs healthcare plans.
- Rural Americans’ worries about their local problems often differ drastically from national views about the country’s problems. Right now, rural Americans are extremely worried about the effects of the opioid crisis, and despite what political ideology might suggest, many of them are hoping that the government can help.
- Companies are exploiting medical data to develop new drugs, and this is raising public concern about issues of privacy and ownership. Others are wondering if they can make money off of their own medical information.
- The Congressional Research Service released several reports in recent months that provide a primer on the ACA’s risk-adjustment program, state innovation waivers, Medicare, federal plan requirements and the marketplaces.